Immunotherapy in urothelial carcinoma: fade or future standard?

Immunotherapy of non-muscle-invasive bladder carcinoma by Bacillus-Calmette-Guérin (BCG) instillation is a well-established treatment option since decades. Despite this fact, the immunocellular basis was first studied in recent years. New aspects of immunotherapy, also for progressed bladder carcino...

Descripción completa

Detalles Bibliográficos
Autores principales: Breyer, Johannes, Burger, Maximilian, Otto, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071200/
https://www.ncbi.nlm.nih.gov/pubmed/27785423
http://dx.doi.org/10.21037/tau.2016.04.06
_version_ 1782461248784302080
author Breyer, Johannes
Burger, Maximilian
Otto, Wolfgang
author_facet Breyer, Johannes
Burger, Maximilian
Otto, Wolfgang
author_sort Breyer, Johannes
collection PubMed
description Immunotherapy of non-muscle-invasive bladder carcinoma by Bacillus-Calmette-Guérin (BCG) instillation is a well-established treatment option since decades. Despite this fact, the immunocellular basis was first studied in recent years. New aspects of immunotherapy, also for progressed bladder carcinoma, might follow promising research on immunological targets.
format Online
Article
Text
id pubmed-5071200
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-50712002016-10-26 Immunotherapy in urothelial carcinoma: fade or future standard? Breyer, Johannes Burger, Maximilian Otto, Wolfgang Transl Androl Urol Review Article Immunotherapy of non-muscle-invasive bladder carcinoma by Bacillus-Calmette-Guérin (BCG) instillation is a well-established treatment option since decades. Despite this fact, the immunocellular basis was first studied in recent years. New aspects of immunotherapy, also for progressed bladder carcinoma, might follow promising research on immunological targets. AME Publishing Company 2016-10 /pmc/articles/PMC5071200/ /pubmed/27785423 http://dx.doi.org/10.21037/tau.2016.04.06 Text en 2016 Translational Andrology and Urology. All rights reserved.
spellingShingle Review Article
Breyer, Johannes
Burger, Maximilian
Otto, Wolfgang
Immunotherapy in urothelial carcinoma: fade or future standard?
title Immunotherapy in urothelial carcinoma: fade or future standard?
title_full Immunotherapy in urothelial carcinoma: fade or future standard?
title_fullStr Immunotherapy in urothelial carcinoma: fade or future standard?
title_full_unstemmed Immunotherapy in urothelial carcinoma: fade or future standard?
title_short Immunotherapy in urothelial carcinoma: fade or future standard?
title_sort immunotherapy in urothelial carcinoma: fade or future standard?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071200/
https://www.ncbi.nlm.nih.gov/pubmed/27785423
http://dx.doi.org/10.21037/tau.2016.04.06
work_keys_str_mv AT breyerjohannes immunotherapyinurothelialcarcinomafadeorfuturestandard
AT burgermaximilian immunotherapyinurothelialcarcinomafadeorfuturestandard
AT ottowolfgang immunotherapyinurothelialcarcinomafadeorfuturestandard

Ejemplares similares